REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune...
Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech
New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies
TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer
Patent covers NT219’s combinations with multiple 2 nd and 3 rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)
Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance
Top Line Results from First Part of the Study Expected in Second Half of 2021
Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...